<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5849279</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1002525</article-id><article-id pub-id-type="publisher-id">PMEDICINE-D-17-02773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Arrhythmia</subject><subj-group><subject>Atrial Fibrillation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular Diseases</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Materials by Attribute</subject><subj-group><subject>Adhesives</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Bioassays and Physiological Analysis</subject><subj-group><subject>Electrophysiological Techniques</subject><subj-group><subject>Cardiac Electrophysiology</subject><subj-group><subject>Electrocardiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Blood Pressure</subject><subj-group><subject>Hypertension</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Myocardial Infarction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Heart Failure</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Genetic risk score for atrial fibrillation</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5288-7462</contrib-id><name><surname>Muse</surname><given-names>Evan D.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wineinger</surname><given-names>Nathan E.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2650-4357</contrib-id><name><surname>Spencer</surname><given-names>Emily G.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Melissa</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>Riley</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9873-6694</contrib-id><name><surname>Zhang</surname><given-names>Yunyue</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>Paddy M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Steven P.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wohlgemuth</surname><given-names>Jay G.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Devlin</surname><given-names>James J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shiffman</surname><given-names>Dov</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Topol</surname><given-names>Eric J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, California, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Division of Cardiovascular Disease, Scripps Clinic–Scripps Health, La Jolla, California, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Quest Diagnostics, San Juan Capistrano, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rahimi</surname><given-names>Kazem</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Oxford, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>JGW is an employee of Quest Diagnostics and receives stock and stock options from Quest Diagnostics. </plain></SENT>
<SENT sid="2" pm="."><plain>SPR, JJD and DS are employees of Quest Diagnostics. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>etopol@scripps.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>15</volume><issue>3</issue><elocation-id>e1002525</elocation-id><history><date date-type="received"><day>8</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 Muse et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Muse et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pmed.1002525.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="3" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>Atrial fibrillation (AF) is the most commonly encountered arrhythmia and is associated with an elevated risk of stroke. </plain></SENT>
<SENT sid="5" pm="."><plain>Improving the identification of patients with the highest risk for AF to enable appropriate surveillance and treatment, if necessary, is critical to reducing AF-associated morbidity and mortality. </plain></SENT>
<SENT sid="6" pm="."><plain>Multiple common single nucleotide polymorphisms (SNPs) are unequivocally associated with the lifetime risk of AF. </plain></SENT>
<SENT sid="7" pm="."><plain>In the current study we aimed to prospectively validate an AF genetic risk score (GRS) in previously undiagnosed patients at risk for AF. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="8" pm="."><plain>Methods and findings </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>Individuals 40 years of age or older with 1 clinical risk factor for AF, presenting with symptoms of AF, or with a first diagnosis of AF, were enrolled for genetic testing and ambulatory cardiac rhythm monitoring with an adhesive patch monitor or a long-term Holter monitor (mean wear time 10 days 21 hours and 13 days 18 hours, respectively). </plain></SENT>
<SENT sid="10" pm="."><plain>An AF event was the first diagnosis of AF by ECG, patch monitor, or long-term Holter monitor. </plain></SENT>
<SENT sid="11" pm="."><plain>The AF GRS was determined for each participant based on the weighted contribution of 12 genetic risk loci. </plain></SENT>
<SENT sid="12" pm="."><plain>Of 904 participants, 85 manifested AF. </plain></SENT>
<SENT sid="13" pm="."><plain>Their mean age was 66.2 (SD 11.8) years; 38% of participants were male. </plain></SENT>
<SENT sid="14" pm="."><plain>Participants in the highest quintile of AF GRS were more likely (odds ratio 3.11; 95% CI 1.27–7.58; p = 0.01) to have had an AF event than participants in the lowest quintile after adjusting for age, sex, smoking status, BMI, hypertension, diabetes mellitus, heart failure, and prior myocardial infarction. </plain></SENT>
<SENT sid="15" pm="."><plain>Study limitations included an ethnically homogenous population, a restricted rhythm monitoring period, and the evolving discovery of SNPs associated with AF. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="16" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>Prospective assessment of a GRS for AF identified participants with elevated risk of AF beyond established clinical criteria. </plain></SENT>
<SENT sid="18" pm="."><plain>Accordingly, a GRS for AF could be incorporated into overall risk assessment to better identify patients at the highest risk of developing AF, although further testing in larger populations is needed to confirm these findings. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="19" pm="."><plain>Trial registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20" pm="."><plain>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01970969">NCT01970969</ext-link> </plain></SENT>
</text></SecTag></p></sec></abstract><abstract abstract-type="toc"><p><SecTag type="ABS"><text><SENT sid="21" pm="."><plain>In prospective cohort study, Eric Topol and colleague validate a genetic risk score for identification of patients at the highest risk of developing atrial fibrillation. </plain></SENT>
</text></SecTag></p></abstract><abstract abstract-type="summary"><title><text><SENT sid="22" pm="."><plain>Author summary </plain></SENT>
</text></title><sec id="sec005"><title><text><SENT sid="23" pm="?"><plain>Why was this study done? </plain></SENT>
</text></title><list list-type="bullet"><list-item><p><SecTag type="ABS"><text><SENT sid="24" pm="."><plain>Atrial fibrillation (AF) is a common heart rhythm disturbance that can lead to devastating strokes. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="25" pm="."><plain>While clinical factors such as age, high blood pressure, and obesity can increase the chances of developing AF, several genetic determinants of AF also play a role. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="26" pm="."><plain>Here we assessed the ability of a genetic risk score (GRS) for AF to identify individuals presenting with symptoms with the highest likelihood of AF on cardiac rhythm monitoring. </plain></SENT>
</text></SecTag></p></list-item></list></sec><sec id="sec006"><title><text><SENT sid="27" pm="?"><plain>What did the researchers do and find? </plain></SENT>
</text></title><list list-type="bullet"><list-item><p><SecTag type="ABS"><text><SENT sid="28" pm="."><plain>Individuals 40 years of age or older with at least 1 clinical risk factor for AF presenting either with symptoms of AF or with the first diagnosis of AF on electrocardiogram were enrolled. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="29" pm="."><plain>A patch-based or long-term Holter cardiac rhythm monitor was fitted to individuals without AF on electrocardiogram, and they were monitored for upwards of 2 weeks. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="30" pm="."><plain>DNA was isolated from a blood sample, and an AF GRS was calculated for each participant. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="31" pm="."><plain>We found that individuals with the highest AF GRSs were 3 times more likely to be diagnosed with AF during the study than participants with the lowest AF GRSs. </plain></SENT>
</text></SecTag></p></list-item></list></sec><sec id="sec007"><title><text><SENT sid="32" pm="?"><plain>What do these findings mean? </plain></SENT>
</text></title><list list-type="bullet"><list-item><p><SecTag type="ABS"><text><SENT sid="33" pm="."><plain>An AF GRS may be incorporated into an overall risk assessment strategy to better identify patients at the highest risk of developing AF. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="34" pm="."><plain>For patients with stroke of unknown origin, a high AF GRS may be helpful to guide diagnostic testing. </plain></SENT>
</text></SecTag></p></list-item><list-item><p><SecTag type="ABS"><text><SENT sid="35" pm="."><plain>In the future, individuals with high AF genomic risk may be able to use this information to help prevent the arrhythmia from occurring. </plain></SENT>
</text></SecTag></p></list-item></list></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>UL1 TR001114</award-id><principal-award-recipient><name><surname>Topol</surname><given-names>Eric J.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>KL2 TR001112</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5288-7462</contrib-id><name><surname>Muse</surname><given-names>Evan D.</given-names></name></principal-award-recipient></award-group><funding-statement>National Institute of Health, National Center for Advancing Translational Science. UL1TR001114 (EJT); National Institute of Health, National Center for Advancing Translational Science. KL2 TR001112 (EDM); Quest Diagnostics, Inc. (SPR, JGW, JJD, DS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec008"><title><text><SENT sid="36" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="37" pm="."><plain>Stroke remains the fifth leading cause of death in the United States, despite increased recognition and better management of overall cardiovascular disease risk, which has led to a decline in stroke mortality [1]. </plain></SENT>
<SENT sid="38" pm="."><plain>More than 750,000 people experience a stroke event each year in the US, with a prevalence of 2.6% in the US adult population [1]. </plain></SENT>
<SENT sid="39" pm="."><plain>While conventional risk factors for stroke—including cigarette smoking, hypertension, diabetes mellitus, dyslipidemia, and heart failure—account for a sizable portion of stroke episodes, atrial fibrillation (AF) is associated with a quarter of all stroke events [2–4]. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>AF is the most common pathological cardiac arrhythmia, present in nearly 6 million people in the US alone, with the prevalence estimated to grow to over 12 million people by 2030 [5]. </plain></SENT>
<SENT sid="41" pm="."><plain>It is not uncommon for AF to remain undetected in asymptomatic individuals. </plain></SENT>
<SENT sid="42" pm="."><plain>AF has been documented in asymptomatic individuals not only in patients with implanted cardiac devices [6,7], but also in population-based screening studies using smartphone electrocardiogram (ECG) sensors [8–11]. </plain></SENT>
<SENT sid="43" pm="."><plain>These efforts to better diagnose subclinical, asymptomatic AF may be useful for implementing appropriate therapies to reduce the risk of stroke [12]. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>To this end, efforts have been made to predict the occurrence of AF using risk scores based on clinical factors associated with disease [13,14]. </plain></SENT>
<SENT sid="45" pm="."><plain>While clinical risk factors for AF (e.g., obesity, hypertension, and obstructive sleep apnea) are well established, risk scores incorporating these factors have fallen short in validation studies [15]. </plain></SENT>
<SENT sid="46" pm="."><plain>Therefore, efforts continue to improve risk prediction by incorporating genetic risk factors. </plain></SENT>
<SENT sid="47" pm="."><plain>Genetic factors are estimated to account for ~40% of a person’s total AF risk [16], and genome-wide association studies (GWASs) of increasing size have identified multiple single nucleotide polymorphisms (SNPs) associated with AF on the genome-wide level [17–23]. </plain></SENT>
<SENT sid="48" pm="."><plain>For AF, several genetic risk scores (GRSs) have been characterized and tested in various studies, illustrating their ability to identify individuals at increased risk of AF [24–29]. </plain></SENT>
<SENT sid="49" pm="."><plain>But some of these findings pertain to a lifetime risk of AF or &gt;14 years of follow-up, and have not yet provided any insight on immediate risk for an individual with established risk factors presenting with symptoms. </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>Here, in this multicenter study of symptomatic participants without prior diagnosis of AF, we aimed to prospectively validate a 12-SNP AF GRS for identifying patients at an increased risk for AF during 2 weeks of ambulatory cardiac rhythm monitoring. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec009"><title><text><SENT sid="51" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="sec010"><title><text><SENT sid="52" pm="."><plain>Participant recruitment and inclusion and exclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>The study was approved by the institutional review board (IRB) at the Scripps Clinic (La Jolla, CA), which provided overall study oversight, in addition to the individual IRBs affiliated with each recruitment center. </plain></SENT>
<SENT sid="54" pm="."><plain>Participants were enrolled from December 2, 2013, through January 19, 2016. </plain></SENT>
<SENT sid="55" pm="."><plain>The complete list of recruitment centers is provided in S1 Table. </plain></SENT>
<SENT sid="56" pm="."><plain>Informed consent was provided by each patient prior to enrollment. </plain></SENT>
<SENT sid="57" pm="."><plain>Patients presenting with any symptoms suggestive of AF determined by the clinician to necessitate ambulatory cardiac rhythm monitoring were evaluated for inclusion in this study. </plain></SENT>
<SENT sid="58" pm="."><plain>Patients were eligible for enrollment if they were 40 years of age or older and were capable of providing informed consent in addition to providing a blood sample for genetic analysis. </plain></SENT>
<SENT sid="59" pm="."><plain>Study participants were also required to have at least 1 of the following clinical characteristics: hypertension, ischemic stroke with no defined etiology within the past 6 months, high BMI (&gt;30 kg/m2), history of heart failure, clinically significant murmur, first degree atrioventricular block (PR interval &gt; 200 ms), chronic kidney disease, hypertrophic cardiomyopathy, congenital heart disease, chronic obstructive pulmonary disease, obstructive sleep apnea, diabetes mellitus, regular excess alcohol consumption (males &gt;14 drinks/week, females &gt;7 drinks/week), or a family history of AF. </plain></SENT>
<SENT sid="60" pm="."><plain>Patients with a prior diagnosis of AF or atrial flutter were excluded. </plain></SENT>
<SENT sid="61" pm="."><plain>Additionally, patients with cardiac surgery (coronary artery bypass grafting, valve replacement or repair, pericardial stripping, etc.) within the previous 30 days, with hyperthyroidism, receiving permanent pacing therapy, with skin allergies or sensitivities to adhesives, or who were anticipated to have exposure to high frequency surgical equipment during the monitoring period were not eligible for enrollment. </plain></SENT>
<SENT sid="62" pm="."><plain>An independent data and safety monitoring board provided ongoing study oversight throughout the trial period. </plain></SENT>
<SENT sid="63" pm="."><plain>This study (S1 Protocol) was registered with ClinicalTrials.gov (NCT01970969) and is reported as per the TRIPOD guidelines (S1 Checklist). </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="64" pm="."><plain>Cardiac rhythm monitoring and event adjudication </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>The primary event was an instance of AF/atrial flutter as defined by standard electrocardiographic criteria for a minimum duration of 5 seconds (AF event). </plain></SENT>
<SENT sid="66" pm="."><plain>AF events were assessed either by ambulatory cardiac rhythm monitoring or on 12-lead ECG. </plain></SENT>
<SENT sid="67" pm="."><plain>Patients meeting the specified inclusion criteria presenting to an outpatient clinic for evaluation of symptoms with high clinical suspicion for AF were either provided an adhesive patch monitor (Zio patch, iRhythm Technologies), if enrolled at centers within the US, or fitted with a long-term Holter monitor (Spiderflash, Soren Group) at Canadian centers. </plain></SENT>
<SENT sid="68" pm="."><plain>Participants were instructed to wear the cardiac rhythm monitor for the life of the device (~2 weeks). </plain></SENT>
<SENT sid="69" pm="."><plain>Symptomatic patients presenting with the first diagnosis of AF on 12-lead ECG were not required to have additional ambulatory cardiac rhythm monitoring. </plain></SENT>
<SENT sid="70" pm="."><plain>Events that were considered possible occurrences of AF were independently adjudicated by 2 separate physicians with expertise in cardiac rhythm interpretation, with a third physician’s review available for incongruent cases. </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="71" pm="."><plain>Genotyping </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>DNA was extracted from whole blood using the MagNA Pure 96 instrument and reagent kit (Roche Life Science). </plain></SENT>
<SENT sid="73" pm="."><plain>SNaPshot multiplex genotyping (Thermo Fisher Scientific) was used to simultaneously genotype 12 SNPs comprising the AF GRS (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"></SecTag><p><text><SENT sid="320" pm="."><plain>In an effort to examine the individual contributions of the 12 SNPs that composed the AF GRS, we evaluated the association of each SNP with AF in both unadjusted and adjusted models (S2 Table), though this study was not well powered to detect individual marker effects. </plain></SENT>
<SENT sid="321" pm="."><plain>Eleven of the 12 SNPs were consistent with prior results: either the direction of the effect allele was consistent with previous reports, or the result was not nominally significant (p &lt; 0.05). </plain></SENT>
<SENT sid="322" pm="."><plain>However, rs10033464 (4q25, PITX2) displayed a risk estimate in the opposite direction than had been previously reported by others. </plain></SENT>
<SENT sid="323" pm="."><plain>This discrepancy appears to be in part due to linkage disequilibrium between this marker and the nearby SNP with the strongest association in this gene, rs2200733 (p = 0.005). </plain></SENT>
<SENT sid="324" pm="."><plain>We and others have observed that the risk alleles at these markers are negatively associated with each other. </plain></SENT>
<SENT sid="325" pm="."><plain>There remains uncertainty in the optimal genetic risk model for AF, and superior models will certainly evolve in the future as more genetic discoveries are made. </plain></SENT>
<SENT sid="326" pm="."><plain>In this light, we also considered a modified AF GRS that included only the most strongly associated SNP in each gene—which is a common solution in GRS estimation to eliminate confounding due to linkage disequilibrium [32]. </plain></SENT>
<SENT sid="327" pm="."><plain>The resulting 9-SNP model included rs2200733 for PITX2 and the other 8 SNPs from the other genes. </plain></SENT>
<SENT sid="328" pm="."><plain>The risk of AF with this modified AF GRS, as in the 12-SNP model, was greater for the highest AF GRS quintile than for the lowest AF GRS quintile (OR 5.07; 95% CI 2.04–12.60; p &lt; 0.001), and this model appeared to better differentiate risk of AF throughout the distribution of genetic risk (S3 Table). </plain></SENT>
<SENT sid="329" pm="."><plain>As expected, the risk estimates derived for both AF GRS models remained significant in an analysis limited to participants who self-reported as white (S4 Table). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec017"><title><text><SENT sid="330" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="331" pm="."><plain>We aimed to assess the ability of a previously developed AF GRS comprising 12 common SNPs (minor allele frequency &gt; 5%) that have been found to be associated with AF at a genome-wide significance level to identify patients at the highest risk of developing AF in a prospective manner. </plain></SENT>
<SENT sid="332" pm="."><plain>Indeed, in this cohort of 904 participants of predominantly white ethnicity, 85 had AF events, and participants in the highest quintile of AF GRS had a risk greater than 3 times that of participants in the lowest AF GRS quintile. </plain></SENT>
<SENT sid="333" pm="."><plain>These findings are consistent with the original report [27] of this specific AF GRS, in addition to other studies utilizing a multi-allele GRS [26,28]; however, all of these studies were conducted on a retrospective basis. </plain></SENT>
</text></p><p><text><SENT sid="334" pm="."><plain>By harnessing advanced technology to realize the benefits of long-term cardiac rhythm monitoring using an adhesive patch monitor in lieu of the dated 24-hour Holter monitor [33], participants were monitored for over 10 days after presenting to a clinic with specific symptoms prompting cardiac rhythm monitoring with a suspicion for AF. </plain></SENT>
<SENT sid="335" pm="."><plain>It has become clear that extended periods of ambulatory cardiac rhythm monitoring increase the yield of AF detection, especially in patients with cryptogenic stroke [34]. </plain></SENT>
<SENT sid="336" pm="."><plain>AF is the most common arrhythmia, and with age being an important risk factor, its prevalence is estimated to increase steadily as humans live longer and with more chronic disease. </plain></SENT>
<SENT sid="337" pm="."><plain>While documented AF accounts for 1 out of every 6 strokes, a quarter of all strokes are initially categorized as “cryptogenic” with no identifiable cause. </plain></SENT>
<SENT sid="338" pm="."><plain>With prolonged rhythm monitoring strategies, many of these cryptogenic strokes are subsequently attributed to AF [12,34–36]. </plain></SENT>
<SENT sid="339" pm="."><plain>An AF GRS may help identify individuals at the highest risk of subclinical and paroxysmal AF who would benefit from a cardiac rhythm monitoring strategy even before a devastating stoke event. </plain></SENT>
<SENT sid="340" pm="."><plain>Improving identification of patients with AF, and initiating appropriate anticoagulant therapies when appropriate, is important given the risk of embolic stroke, which is more likely to be associated with major neurological deficits than non-embolic stroke [37]. </plain></SENT>
</text></p><p><text><SENT sid="341" pm="."><plain>To date, the relative risk of AF associated with individual SNPs ranges from just above 1 to a highest value of 1.64 (rs6817105, PITX2). </plain></SENT>
<SENT sid="342" pm="."><plain>Thus, the ability to combine common SNPs into an AF GRS with the ability to differentiate a greater than 3-fold increased risk of AF in a population on a prospective basis may be useful. </plain></SENT>
<SENT sid="343" pm="."><plain>Such a panel of SNPs could be assayed at low cost and be used in conjunction with an evaluation of a patient with possible AF. </plain></SENT>
<SENT sid="344" pm="."><plain>For example, even 10 days of patch-based monitoring may not yield the diagnosis of subclinical AF and indicate that additional monitoring would be useful [34,35]. </plain></SENT>
</text></p><p><text><SENT sid="345" pm="."><plain>Several limitations of our study should be examined. </plain></SENT>
<SENT sid="346" pm="."><plain>Despite our efforts to recruit patients from various geographic regions across the US and Canada ranging from rural to urban settings, the vast majority of participants (93%) self-reported as white, with only minor representation from other ethnicities. </plain></SENT>
<SENT sid="347" pm="."><plain>The bulk of our understanding of genetic variants in association with disease has come from GWASs in populations of European ancestry, such that considerable assessment in other ancestries is important, and the 12-SNP panel we used in the study cannot be extrapolated beyond those of European ancestry [38,39]. </plain></SENT>
<SENT sid="348" pm="."><plain>With the inclusion of more ethnically diverse populations in genetic studies, the importance of ethnicity in determining the association of SNPs with disease will be magnified and will certainly need to be accounted for in future GRS calculations [40,41]. </plain></SENT>
<SENT sid="349" pm="."><plain>It was recently shown that rs10824026 (10q22), 1 of the SNPs utilized in the current AF GRS, conferred a greater risk for AF in white individuals than in black individuals [42]. </plain></SENT>
<SENT sid="350" pm="."><plain>Although the current study is underpowered to assess AF risk by ethnicity, self-identified African-American participants in this study were far more likely to carry the risk allele (G) (53% GA and 38% GG) compared to self-identified white participants (26% GA and 2% GG). </plain></SENT>
</text></p><p><text><SENT sid="351" pm="."><plain>Since the initiation of our study, additional SNPs associated with AF have been identified, and we expect this trend to continue as the genetic datasets expand. </plain></SENT>
<SENT sid="352" pm="."><plain>Our AF GRS did not include 5 recently discovered SNPs [43], though 1 of these SNPs was specific for a Japanese population and the others had lower relative risks than the SNPs already included in our AF GRS. </plain></SENT>
<SENT sid="353" pm="."><plain>Additionally, our preliminary finding that demonstrated greater differentiation in AF based on a 9-SNP (1 SNP per gene) model simply shows that improvements can be made. </plain></SENT>
<SENT sid="354" pm="."><plain>Future efforts in developing polygenetic risk predictors of AF should focus on optimizing the set of markers and, potentially, population-specific weights assigned to individual markers. </plain></SENT>
<SENT sid="355" pm="."><plain>Yet, improving the predictive performance of a risk score solely based on genetic data will reach an upper limit [44]. </plain></SENT>
<SENT sid="356" pm="."><plain>As additional AF biomarkers are determined through multi-omics approaches (proteomics, lipidomics, and metabolomics) or multiparameter physiological sensors, the addition of more complex clinical, physiological, and biomarker components to the AF GRS will be an exciting next step to developing a comprehensive AF risk score. </plain></SENT>
</text></p><p><text><SENT sid="357" pm="."><plain>In terms of AF events, the mean monitoring time for patients evaluated with adhesive patch monitoring was less than 11 days, and there could have been patients for whom we did not capture their AF event during this time. </plain></SENT>
<SENT sid="358" pm="."><plain>Prolonged monitoring periods, as have been achieved using implantable monitoring devices, have been shown to detect increasingly more AF events over time, especially in patients with cryptogenic stroke [34–36]. </plain></SENT>
<SENT sid="359" pm="."><plain>Currently, there is little guidance regarding optimal length of monitoring. </plain></SENT>
<SENT sid="360" pm="."><plain>While we do not feel that the future of diagnostic ambulatory cardiac rhythm monitoring is grounded in expensive, implantable devices, this role may instead be filled using unobtrusive and passive wearables. </plain></SENT>
<SENT sid="361" pm="."><plain>A SNP-based AF GRS, however, provides a fixed overall lifetime genetic risk assessment for AF, and given the short-term follow-up time in the current study, we expect that the ability of the AF GRS to identify individuals with the highest AF risk would likely increase with a longer monitoring period and follow-up. </plain></SENT>
<SENT sid="362" pm="."><plain>Likewise, we illustrate the strength of a GRS-based approach to disease screening and demonstrate the ability of the AF GRS to temporally stratify symptomatic patients with the probability of an AF diagnosis during 2 weeks of rhythm monitoring. </plain></SENT>
<SENT sid="363" pm="."><plain>In doing so, we have moved from the typical retrospective GWAS, without temporal association, to a prospective GRS screen that leverages the genomic risk for an individual under evaluation. </plain></SENT>
</text></p><p><text><SENT sid="364" pm="."><plain>In conclusion, we prospectively validated a GRS for AF that may prove useful in the diagnostic evaluation of certain individuals who are being assessed for subclinical presence of this arrhythmia, and potentially as a means to help its prevention in the future. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec018"><title><text><SENT sid="365" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pmed.1002525.s001"><label>S1 Checklist</label><caption><title><text><SENT sid="366" pm="."><plain>TRIPOD checklist. </plain></SENT>
</text></title><p><text><SENT sid="367" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s001.pdf"><caption><p><text><SENT sid="368" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s002"><label>S1 Text</label><caption><title><text><SENT sid="369" pm="."><plain>Reported SNPs for study population. </plain></SENT>
</text></title><p><text><SENT sid="370" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s002.docx"><caption><p><text><SENT sid="371" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s003"><label>S1 Protocol</label><caption><title><text><SENT sid="372" pm="."><plain>Study protocol. </plain></SENT>
</text></title><p><text><SENT sid="373" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s003.pdf"><caption><p><text><SENT sid="374" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s004"><label>S1 Table</label><caption><title><text><SENT sid="375" pm="."><plain>US and Canadian patient recruitment centers. </plain></SENT>
</text></title><p><text><SENT sid="376" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s004.pdf"><caption><p><text><SENT sid="377" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s005"><label>S2 Table</label><caption><title><text><SENT sid="378" pm="."><plain>Performance of the individual SNPs of the AF GRS. </plain></SENT>
</text></title><p><text><SENT sid="379" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s005.pdf"><caption><p><text><SENT sid="380" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s006"><label>S3 Table</label><caption><title><text><SENT sid="381" pm="."><plain>Risk estimates of AF events according to AF GRS quintile (9-SNP model). </plain></SENT>
</text></title><p><text><SENT sid="382" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s006.pdf"><caption><p><text><SENT sid="383" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1002525.s007"><label>S4 Table</label><caption><title><text><SENT sid="384" pm="."><plain>Risk estimates for both the 12-SNP and 9-SNP AF GRS. </plain></SENT>
</text></title><p><text><SENT sid="385" pm="."><plain>(PDF) </plain></SENT>
</text></p></caption><media xlink:href="pmed.1002525.s007.pdf"><caption><p><text><SENT sid="386" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="387" pm="."><plain>This study could not have been done without the selflessness and generosity of our patients, who deserve our greatest appreciation. </plain></SENT>
<SENT sid="388" pm="."><plain>Additionally, we thank the many research coordinators, nurses, and physicians at each of the clinical enrollment sites for their support of this study. </plain></SENT>
<SENT sid="389" pm="."><plain>Adhesive patch monitors were kindly supplied by iRhythm Technologies. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>AF</term><def><p>atrial fibrillation</p></def></def-item><def-item><term>ECG</term><def><p>electrocardiogram</p></def></def-item><def-item><term>GRS</term><def><p>genetic risk score</p></def></def-item><def-item><term>GWAS</term><def><p>genome-wide association study</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pmed.1002525.ref001"><text><SENT sid="390" pm="."><plain>1Writing Group Members, MozaffarianD, BenjaminEJ, GoAS, ArnettDK, BlahaMJ, et al Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133: e38–360. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIR.0000000000000350">10.1161/CIR.0000000000000350</ext-link> <?supplied-pmid 26673558?>26673558 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref002"><text><SENT sid="391" pm="."><plain>2HealeyJS, ConnollySJ, GoldMR, IsraelCW, Van GelderIC, CapucciA, et al Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1105575">10.1056/NEJMoa1105575</ext-link> <?supplied-pmid 22236222?>22236222 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref003"><text><SENT sid="392" pm="."><plain>3WolfPA, KannelWB, ThomasHE, DawberTR. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology. 1978;28:973–7. <?supplied-pmid 570666?>570666 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref004"><text><SENT sid="393" pm="."><plain>4WolfPA, AbbottRD, KannelWB. Atrial fibrillation: a major contributor to stroke in the elderly. </plain></SENT>
<SENT sid="394" pm="."><plain>The Framingham study. Arch Intern Med. 1987;147:1561–4. <?supplied-pmid 3632164?>3632164 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref005"><text><SENT sid="395" pm="."><plain>5ColillaS, CrowA, PetkunW, SingerDE, SimonT, LiuX. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–7. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2013.05.063">10.1016/j.amjcard.2013.05.063</ext-link> <?supplied-pmid 23831166?>23831166 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref006"><text><SENT sid="396" pm="."><plain>6GlotzerTV, HellkampAS, ZimmermanJ, SweeneyMO, YeeR, MarinchakR, et al Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003;107:1614–9. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.CIR.0000057981.70380.45">10.1161/01.CIR.0000057981.70380.45</ext-link> <?supplied-pmid 12668495?>12668495 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref007"><text><SENT sid="397" pm="."><plain>7GlotzerTV, DaoudEG, WyseDG, SingerDE, EzekowitzMD, HilkerC, et al The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–80. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCEP.109.849638">10.1161/CIRCEP.109.849638</ext-link> <?supplied-pmid 19843914?>19843914 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref008"><text><SENT sid="398" pm="."><plain>8KaasenbroodF, HollanderM, RuttenFH, GerhardsLJ, HoesAW, TielemanRG. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace. 2016;18:1514–20. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/europace/euv426">10.1093/europace/euv426</ext-link> <?supplied-pmid 26851813?>26851813 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref009"><text><SENT sid="399" pm="."><plain>9ChanN, ChoyC. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart. 2017;103:24–31. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/heartjnl-2016-309993">10.1136/heartjnl-2016-309993</ext-link> <?supplied-pmid 27733533?>27733533 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref010"><text><SENT sid="400" pm="."><plain>10LowresN, NeubeckL, SalkeldG, KrassI, McLachlanAJ, RedfernJ, et al Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. </plain></SENT>
<SENT sid="401" pm="."><plain>The SEARCH-AF study. Thromb Haemost. 2014;111:1167–76. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1160/TH14-03-0231">10.1160/TH14-03-0231</ext-link> <?supplied-pmid 24687081?>24687081 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref011"><text><SENT sid="402" pm="."><plain>11SvennbergE, EngdahlJ, Al-KhaliliF, FribergL, FrykmanV, RosenqvistM. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131:2176–84. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.114.014343">10.1161/CIRCULATIONAHA.114.014343</ext-link> <?supplied-pmid 25910800?>25910800 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref012"><text><SENT sid="403" pm="."><plain>12HessPL, HealeyJS, GrangerCB, ConnollySJ, ZieglerPD, AlexanderJH, et al the role of cardiovascular implantable electronic devices in the detection and treatment of subclinical atrial fibrillation. JAMA Cardiol. 2017;;2:324–31. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.5167">10.1001/jamacardio.2016.5167</ext-link> <?supplied-pmid 28097334?>28097334 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref013"><text><SENT sid="404" pm="."><plain>13AlonsoA, NorbyFL. Predicting atrial fibrillation and its complications. Circ J. 2016;80:1061–6. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1253/circj.CJ-16-0239">10.1253/circj.CJ-16-0239</ext-link> <?supplied-pmid 27008924?>27008924 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref014"><text><SENT sid="405" pm="."><plain>14ChristophersenIE, YinX, LarsonMG, LubitzSA, MagnaniJW, McManusDD, et al A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J. 2016;178:45–54. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2016.05.004">10.1016/j.ahj.2016.05.004</ext-link> <?supplied-pmid 27502851?>27502851 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref015"><text><SENT sid="406" pm="."><plain>15KolekMJ, GravesAJ, XuM, BianA, TeixeiraPL, ShoemakerMB, et al Evaluation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records. JAMA Cardiol. 2016;1:1007–13. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.3366">10.1001/jamacardio.2016.3366</ext-link> <?supplied-pmid 27732699?>27732699 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref016"><text><SENT sid="407" pm="."><plain>16LubitzSA, YinX, FontesJD, MagnaniJW, RienstraM, PaiM, et al Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304:2263–9. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.2010.1690">10.1001/jama.2010.1690</ext-link> <?supplied-pmid 21076174?>21076174 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref017"><text><SENT sid="408" pm="."><plain>17GudbjartssonDF, ArnarDO, HelgadottirA, GretarsdottirS, HolmH, SigurdssonA, et al Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353–7. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature06007">10.1038/nature06007</ext-link> <?supplied-pmid 17603472?>17603472 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref018"><text><SENT sid="409" pm="."><plain>18LubitzSA, SinnerMF, LunettaKL, MakinoS, PfeuferA, RahmanR, et al Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation. 2010;122:976–84. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.109.886440">10.1161/CIRCULATIONAHA.109.886440</ext-link> <?supplied-pmid 20733104?>20733104 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref019"><text><SENT sid="410" pm="."><plain>19BenjaminEJ, RiceKM, ArkingDE, PfeuferA, van NoordC, SmithAV, et al Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet. 2009;41:879–81. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.416">10.1038/ng.416</ext-link> <?supplied-pmid 19597492?>19597492 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref020"><text><SENT sid="411" pm="."><plain>20EllinorPT, LunettaKL, GlazerNL, PfeuferA, AlonsoA, ChungMK, et al Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42:240–4. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.537">10.1038/ng.537</ext-link> <?supplied-pmid 20173747?>20173747 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref021"><text><SENT sid="412" pm="."><plain>21EllinorPT, LunettaKL, AlbertCM, GlazerNL, RitchieMD, SmithAV, et al Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–5. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.2261">10.1038/ng.2261</ext-link> <?supplied-pmid 22544366?>22544366 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref022"><text><SENT sid="413" pm="."><plain>22ChristophersenIE, RienstraM, RoselliC, YinX, GeelhoedB, BarnardJ, et al Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49:946–52. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.3843">10.1038/ng.3843</ext-link> <?supplied-pmid 28416818?>28416818 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref023"><text><SENT sid="414" pm="."><plain>23TuckerNR, ClaussS, EllinorPT. Common variation in atrial fibrillation: navigating the path from genetic association to mechanism. Cardiovasc Res. 2016;109:493–501. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cvr/cvv283">10.1093/cvr/cvv283</ext-link> <?supplied-pmid 26733238?>26733238 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref024"><text><SENT sid="415" pm="."><plain>24GoldsteinBA, YangL, SalfatiE, AssimesTL. Contemporary considerations for constructing a genetic risk score: an empirical approach. Genet Epidemiol. 2015;39:439–45. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/gepi.21912">10.1002/gepi.21912</ext-link> <?supplied-pmid 26198599?>26198599 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref025"><text><SENT sid="416" pm="."><plain>25SmithJA, WareEB, MiddhaP, BeacherL, KardiaSLR. Current applications of genetic risk scores to cardiovascular outcomes and subclinical phenotypes. Curr Epidemiol Rep. 2015;2:180–90. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40471-015-0046-4">10.1007/s40471-015-0046-4</ext-link> <?supplied-pmid 26269782?>26269782 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref026"><text><SENT sid="417" pm="."><plain>26EverettBM, CookNR, ConenD, ChasmanDI, RidkerPM, AlbertCM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J. 2013;34:2243–51. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/eht033">10.1093/eurheartj/eht033</ext-link> <?supplied-pmid 23444395?>23444395 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref027"><text><SENT sid="418" pm="."><plain>27TadaH, ShiffmanD, SmithJG, SjögrenM, LubitzSA, EllinorPT, et al Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke. 2014;45:2856–62. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.114.006072">10.1161/STROKEAHA.114.006072</ext-link> <?supplied-pmid 25123217?>25123217 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref028"><text><SENT sid="419" pm="."><plain>28LubitzSA, LunettaKL, LinH, ArkingDE, TrompetS, LiG, et al Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol. 2014;63:1200–10. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2013.12.015">10.1016/j.jacc.2013.12.015</ext-link> <?supplied-pmid 24486271?>24486271 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref029"><text><SENT sid="420" pm="."><plain>29LubitzSA, YinX, LinHJ, KolekM, SmithJG, TrompetS, et al Genetic risk prediction of atrial fibrillation. Circulation. 2017;135:1311–20. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.116.024143">10.1161/CIRCULATIONAHA.116.024143</ext-link> <?supplied-pmid 27793994?>27793994 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref030"><text><SENT sid="421" pm="."><plain>30SchnabelRB, SullivanLM, LevyD, PencinaMJ, MassaroJM, D’AgostinoRB, et al Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739–45. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(09)60443-8">10.1016/S0140-6736(09)60443-8</ext-link> <?supplied-pmid 19249635?>19249635 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref031"><text><SENT sid="422" pm="."><plain>31LiaoJ, KhalidZ, ScallanC, MorilloC, O’DonnellM. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke. 2007;38:2935–40. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.106.478685">10.1161/STROKEAHA.106.478685</ext-link> <?supplied-pmid 17901394?>17901394 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref032"><text><SENT sid="423" pm="."><plain>32MegaJL, StitzielNO, SmithJG, ChasmanDI, CaulfieldMJ, DevlinJJ, et al Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264–71. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(14)61730-X">10.1016/S0140-6736(14)61730-X</ext-link> <?supplied-pmid 25748612?>25748612 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref033"><text><SENT sid="424" pm="."><plain>33BarrettPM, KomatireddyR, HaaserS, TopolS, SheardJ, EncinasJ, et al Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127:95.e11–7. </plain></SENT>
</text></ref><ref id="pmed.1002525.ref034"><text><SENT sid="425" pm="."><plain>34SannaT, DienerH-C, PassmanRS, Di LazzaroV, BernsteinR a, MorilloCA, et al Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–86. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1313600">10.1056/NEJMoa1313600</ext-link> <?supplied-pmid 24963567?>24963567 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref035"><text><SENT sid="426" pm="."><plain>35GladstoneDJ, SpringM, DorianP, PanzovV, ThorpeKE, HallJ, et al Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–77. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1311376">10.1056/NEJMoa1311376</ext-link> <?supplied-pmid 24963566?>24963566 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref036"><text><SENT sid="427" pm="."><plain>36KishoreA, VailA, MajidA, DawsonJ, LeesKR, TyrrellPJ, et al Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520–6. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.113.003433">10.1161/STROKEAHA.113.003433</ext-link> <?supplied-pmid 24385275?>24385275 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref037"><text><SENT sid="428" pm="."><plain>37ArboixA, AlióJ. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150–61. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/157340310791658730">10.2174/157340310791658730</ext-link> <?supplied-pmid 21804774?>21804774 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref038"><text><SENT sid="429" pm="."><plain>38PopejoyAB, FullertonSM. Genomics is failing on diversity. Nature. 2016;538:161–4. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/538161a">10.1038/538161a</ext-link> <?supplied-pmid 27734877?>27734877 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref039"><text><SENT sid="430" pm="."><plain>39MarcusGM, AlonsoA, PeraltaCA, LettreG, VittinghoffE, LubitzSA, et al European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122:2009–15. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.110.958306">10.1161/CIRCULATIONAHA.110.958306</ext-link> <?supplied-pmid 21098467?>21098467 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref040"><text><SENT sid="431" pm="."><plain>40ManraiAK, FunkeBH, RehmHL, OlesenMS, MaronBA, SzolovitsP, et al Genetic misdiagnoses and the potential for health disparities. N Engl J Med. 2016;375:655–65. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMsa1507092">10.1056/NEJMsa1507092</ext-link> <?supplied-pmid 27532831?>27532831 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref041"><text><SENT sid="432" pm="."><plain>41RosenbergNA, HuangL, JewettEM, SzpiechZA, JankovicI, BoehnkeM. Genome-wide association studies in diverse populations. Nat Rev Genet. 2010;11:356–66. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg2760">10.1038/nrg2760</ext-link> <?supplied-pmid 20395969?>20395969 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref042"><text><SENT sid="433" pm="."><plain>42RobertsJD, HuD, HeckbertSR, AlonsoA, DewlandTA, VittinghoffE, et al Genetic investigation into the differential risk of atrial fibrillation among black and white individuals. JAMA Cardiol. 2016;1:442–50. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2016.1185">10.1001/jamacardio.2016.1185</ext-link> <?supplied-pmid 27438321?>27438321 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref043"><text><SENT sid="434" pm="."><plain>43SinnerMF, TuckerNR, LunettaKL, OzakiK, SmithJG, TrompetS, et al Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation. 2014;130:1225–35. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.114.009892">10.1161/CIRCULATIONAHA.114.009892</ext-link> <?supplied-pmid 25124494?>25124494 </plain></SENT>
</text></ref><ref id="pmed.1002525.ref044"><text><SENT sid="435" pm="."><plain>44ManolioTA. Bringing genome-wide association findings into clinical use. Nat Rev Genet. 2013;14:549–58. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg3523">10.1038/nrg3523</ext-link> <?supplied-pmid 23835440?>23835440 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
